DEC 13, 2018 9:00 AM PST

Optimizing Treatment Options for HER2+/ ER+ Breast Cancer using Models of Endocrine Resistance

Speaker
  • Postdoctoral Fellow, Georgetown University Lombardi Comprehensive Cancer Center
    Biography
      Dr. Hillary Stires is a postdoctoral fellow training in the Tumor Biology program funded through a T32 Ruth L. Kirschstein National Research Service Award at Georgetown University Lombardi Comprehensive Cancer Center under the mentorship of Dr. Rebecca Riggins. Dr. Stires received her PhD from Rutgers University in Endocrinology and Animal Biosciences and has always been interested in how steroid hormones (specifically estrogen) influence breast cancer development. In Dr. Riggins lab, Hillary's work focuses on the endocrine resistance in breast cancer. She uses cell culture models of endocrine resistance to compare resistant and parental cell lines, which are then compared with clinical data to ensure clinical relevance. At Georgetown, Hillary initiated the re-establishment of the Georgetown Postdoc Association to foster camaraderie and organize career development activities specifically geared towards postdocs. During the summer of 2019, Dr. Stires will Chair the Hormone-Dependent Cancers Gordon Research Conference. Additionally, Dr. Stires interacts with other scientists, medical oncologists, and patient advocates to improve science communication. She tweets weekly with the group #BCSM (breast cancer social media) to help provide evidence-based education and support for people affected by breast cancer.

    Abstract
    DATE:   December 13, 2018
    TIME:    09:00am PST, 12:00pm EST
     
    Breast cancers are classified into three main subtypes according to their receptor status: estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-positive (HER2+), and triple negative. These classifications provide information about the biology of the disease and help clinicians determine which treatments to use for patients. Targeted therapy for HER2+ breast cancer, including trastuzamab and pertuzamab, and for ER+ breast cancer, including Tamoxifen and aromatase inhibitors, have drastically improved survival outcomes for patients with these disease subtypes. However, when tumors are both HER2+ and ER+, treatment decisions and outcomes are less clear. HER2+/ER+ breast cancers treated with HER2 targeted therapies do not respond as well as HER2+/ER-negative tumors. Our lab is interested in understanding the biology behind these differences in response as well as better defining treatment options for HER2+/ER+ breast cancer. We have established long-term estrogen deprived (LTED) cell models of HER2+/ER+ breast cancer utilizing phenol-red free media as a surrogate for aromatase inhibitor treatment and Fulvestrant (a selective estrogen receptor degrader) resistant cell lines using increasing doses of Fulvestrant over time. We are testing combination therapy over different time courses then measure proliferation and targets of downstream signaling including protein phosphorylation by western blot and gene transcription by qRTPCR. Ultimately, these results will help inform clinicians about the most effective treatment for patients with HER2+/ER+ breast cancer.
     
    Learning Objectives:
    • Understand how scientists use cell culture to model endocrine resistance in breast cancer
    • Decipher differences between breast cancer subtypes and treatment options
    • Describe changes in signaling pathways that occur during endocrine resistance 

    Show Resources
    You May Also Like
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 11, 2021 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    JUN 09, 2021 7:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    MAR 16, 2021 10:00 AM PDT
    C.E. CREDITS
    MAR 16, 2021 10:00 AM PDT
    Date: March 16, 2021 Time: 10:00am (PST) Scientific progress and breakthroughs today are often too expensive for most institutions to acquire. Each year, the National Institutes of Health (N...
    NOV 18, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 18, 2020 8:00 AM PST
    DATE: November 18, 2020 TIME: 08:00am PDT We develop and implement technologies to solve some of the major bottlenecks in biomedical research. In particular, we establish new imaging approac...
    DEC 13, 2018 9:00 AM PST

    Optimizing Treatment Options for HER2+/ ER+ Breast Cancer using Models of Endocrine Resistance


    Specialty

    Cancer Research

    Molecular Biology

    Cell Biology

    Clinical Diagnostics

    Immunology

    Biotechnology

    Genetics

    Cancer Therapeutics

    Cancer Diagnostics

    Clinical Research

    Medicine

    Molecular Diagnostics

    Laboratory Testing

    Biomarkers

    Biochemistry

    Geography

    North America66%

    Europe15%

    Asia12%

    Africa4%

    South America3%

    Registration Source

    Website Visitors54%

    Email Promotions31%

    WAVE Newsletter Promotion4%

    Social Media Promotions2%

    Other7%

    Job Title

    Medical Laboratory Technician20%

    Student13%

    Research Scientist11%

    Executive9%

    Medical Doctor/Specialist8%

    Clinical Laboratory Scientist7%

    Facility/Department Manager6%

    Educator/Faculty6%

    Scientist5%

    Lab Management5%

    Post Doc3%

    QC/QA2%

    Chemist2%

    Consultant2%

    Veterinarian1%

    Pharmacist1%

    Organization

    Academic Institution20%

    Hospital18%

    Clinical Laboratory15%

    Research Institute6%

    Biotech Company6%

    Medical Center5%

    Government4%

    Pharmaceutical Company3%

    Life Science Company3%

    Medical School3%

    Non-Profit Organization2%

    Medical Device Company2%

    Consultant1%

    Ambulatory Care1%

    Other2%


    Show Resources
    Loading Comments...
    Show Resources
    Attendees
    • See more